Skip to main content

Chronic Myelomonocytic Leukemia clinical trials at UCSF

1 research study open to eligible people

Chronic Myelomonocytic Leukemia is a type of cancer. UCSF is looking for people to take part in a clinical trial studying an experimental treatment called IO-202. The trial will test the safety and effectiveness of IO-202 in patients with AML and CMML. The goal is to find the right dose of IO-202 that can help treat the disease.

Showing trials for
  • IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

    open to eligible people ages 18 years and up

    To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differentiation and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D)

    San Francisco, California and other locations

Last updated: